{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:17:42Z","timestamp":1768879062396,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CMRPG3H1261"],"award-info":[{"award-number":["CMRPG3H1261"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CGRPG2F0011"],"award-info":[{"award-number":["CGRPG2F0011"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2C0021"],"award-info":[{"award-number":["CLRPG2C0021"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2C0022"],"award-info":[{"award-number":["CLRPG2C0022"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2C0023"],"award-info":[{"award-number":["CLRPG2C0023"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2C0024"],"award-info":[{"award-number":["CLRPG2C0024"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2G0081"],"award-info":[{"award-number":["CLRPG2G0081"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2G0082"],"award-info":[{"award-number":["CLRPG2G0082"]}]},{"name":"Chang Gung Memorial Hospital, Taiwan","award":["CLRPG2H0041"],"award-info":[{"award-number":["CLRPG2H0041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atorvastatin 40\u00a0mg (ATOR 40) and ezetimibe 10\u00a0mg\/simvastatin 20\u00a0mg (EZ-SIM 20) have similar reductions of low-density lipoprotein cholesterol (LDL-C) but cardiovascular (CV) outcomes between these two therapies are unclear. Our real-world cohort study is to test the hypothesis of pleiotropic effects of purely higher dose statin on CV outcomes beyond similar reductions of LDL-C, especially for extremely CV risk patients. Between January 1, 2007 and December 31, 2013, a total of 3,372 patients with type 2 diabetes mellitus (T2DM) admitted due to acute coronary syndrome (ACS) or acute ischemic stroke (AIS) were selected as the study cohort from the Taiwan National Health Insurance Research Database. Clinical outcomes were evaluated by ATOR 40 group (n\u2009=\u20091686) matched with EZ-SIM 20 group (n\u2009=\u20091686). Primary composite outcome includes CV death, non-fatal myocardial infarction, and non-fatal stroke. Secondary composite outcome includes hospitalization for unstable angina (HUA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). With a mean follow-up of 2.4\u00a0years, no significant difference of primary composite outcome was observed between ATOR 40 and EZ-SIM 20 groups (subdistribution hazard ratio [SHR], 1.09; 95% confidence interval [CI], 0.95\u20131.25). Nevertheless, ATOR 40 group had lower risks of HUA (SHR, 0.50; 95% CI, 0.35\u20130.72), PCI (SHR, 0.82; 95% CI, 0.69\u20130.97) and CABG (SHR, 0.62; 95% CI, 0.40\u20130.97) than EZ-SIM 20 group. For T2DM patients after ACS or AIS, ATOR 40 and EZ-SIM 20 had similar major CV outcomes, which still supported the main driver for CV risk reductions is LDL-C lowering.<\/jats:p>","DOI":"10.1038\/s41598-021-86090-9","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:04:44Z","timestamp":1616497484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks"],"prefix":"10.1038","volume":"11","author":[{"given":"Yu-Cheng","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawl-Shan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Tai","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jui","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"86090_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229\u2013234 (1998).","journal-title":"N. Engl. J. Med."},{"key":"86090_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani, A. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 379, 633\u2013644 (2018).","journal-title":"N. Engl. J. Med."},{"key":"86090_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/hrt.2004.035766","volume":"90","author":"F Boccara","year":"2004","unstructured":"Boccara, F. & Cohen, A. Interplay of diabetes and coronary heart disease on cardiovascular mortality. Heart 90, 1371\u20131373 (2004).","journal-title":"Heart"},{"key":"86090_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.04.004","volume":"24","author":"J Shou","year":"2015","unstructured":"Shou, J., Zhou, L., Zhu, S. & Zhang, X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J. Stroke Cerebrovasc. Dis. 24, 1961\u20131968 (2015).","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"86090_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/CS-2018-0535","volume":"25","author":"AJ Garber","year":"2019","unstructured":"Garber, A. J. et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2019 Executive Summary. Endocr. Pract. 25, 69\u2013100 (2019).","journal-title":"Endocr. Pract."},{"key":"86090_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jfma.2016.11.013","volume":"116","author":"YH Li","year":"2017","unstructured":"Li, Y. H. et al. 2017 Taiwan lipid guidelines for high risk patients. J. Formos. Med. Assoc. 116, 217\u2013248 (2017).","journal-title":"J. Formos. Med. Assoc."},{"key":"86090_CR7","unstructured":"Grundy, S.M., Stone, N.J., Bailey, A.L., et al., AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018."},{"key":"86090_CR8","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"C Disease","year":"2019","unstructured":"Disease, C. & Management, R. Standards of medical care in diabetes-2019. Diabetes Care 42, S103\u2013S123 (2019).","journal-title":"Diabetes Care"},{"key":"86090_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"key":"86090_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","volume":"140","author":"Y Ouchi","year":"2019","unstructured":"Ouchi, Y. et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 140, 992\u20131003 (2019).","journal-title":"Circulation"},{"key":"86090_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097\u20132107 (2018).","journal-title":"N. Engl. J. Med."},{"key":"86090_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"86090_CR13","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","volume":"256","author":"J Stamler","year":"1986","unstructured":"Stamler, J., Wentworth, D. & Neaton, J. D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256, 2823\u20132828 (1986).","journal-title":"JAMA"},{"key":"86090_CR14","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1210\/jcem.85.6.6642-1","volume":"85","author":"CM Ballantyne","year":"2000","unstructured":"Ballantyne, C. M. et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J. Clin. Endocrinol. Metab. 85, 2089\u20132112 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"86090_CR15","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent, C. et al. Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670\u20131681 (2010).","journal-title":"Lancet"},{"key":"86090_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone, N. J. et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1-45 (2014).","journal-title":"Circulation"},{"key":"86090_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","volume":"149","author":"CM Ballantyne","year":"2005","unstructured":"Ballantyne, C. M., Abate, N., Yuan, Z., King, T. R. & Palmisano, J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 149, 464\u2013473 (2005).","journal-title":"Am Heart J."},{"key":"86090_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ahj.2005.10.009","volume":"151","author":"ID Galin","year":"2006","unstructured":"Galin, I. D. & Smith, D. A. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J. 151, e1 (2006).","journal-title":"Am Heart J."},{"key":"86090_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.03.002","volume":"240","author":"L Masana","year":"2015","unstructured":"Masana, L., Pedro-Botet, J. & Civeira, F. IMPROVE-IT clinical implications. Should the \u201chigh-intensity cholesterol-lowering therapy\u201d strategy replace the \u201chigh-intensity statin therapy\u201d?. Atherosclerosis 240, 161\u2013162 (2015).","journal-title":"Atherosclerosis"},{"issue":"99","key":"86090_CR20","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.amjcard.2007.01.062","volume":"15","author":"T Pearson","year":"2007","unstructured":"Pearson, T. et al. Comparison of effects of ezetimibe\/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 15(99), 1706\u20131713 (2007).","journal-title":"Am J Cardiol."},{"key":"86090_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao, J. K. & Laufs, U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89\u2013118 (2005).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"86090_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle, A., Laufs, U. & Liao, J. K. Pleiotropic effects of statins on the cardiovascular system. Circ. Res. 120, 229\u2013243 (2017).","journal-title":"Circ. Res."},{"key":"86090_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2174\/1570161116666180817155058","volume":"17","author":"A Oesterle","year":"2019","unstructured":"Oesterle, A. & Liao, J. K. The pleiotropic effects of statins\u2014from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. Curr. Vasc. Pharmacol. 17, 222\u2013232 (2019).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"86090_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.108.813311","volume":"119","author":"PY Liu","year":"2009","unstructured":"Liu, P. Y., Liu, Y. W., Lin, L. J., Chen, J. H. & Liao, J. K. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119, 131\u2013138 (2009).","journal-title":"Circulation"},{"key":"86090_CR25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/eurheartj\/ehi881","volume":"27","author":"S Fichtlscherer","year":"2006","unstructured":"Fichtlscherer, S. et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for \u201cpleiotropic\u201d functions of statin therapy. Eur. Heart J. 27, 1182\u20131190 (2006).","journal-title":"Eur. Heart J."},{"key":"86090_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2012.04.003","volume":"223","author":"G Rudofsky","year":"2012","unstructured":"Rudofsky, G. et al. Identical LDL-cholesterol lowering but non-identical effects on NF-kappaB activity: high dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis 223, 190\u2013196 (2012).","journal-title":"Atherosclerosis"},{"key":"86090_CR27","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1253\/circj.CJ-13-0033","volume":"77","author":"Y Matsue","year":"2013","unstructured":"Matsue, Y., Matsumura, A., Suzuki, M., Hashimoto, Y. & Yoshida, M. Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial. Circ. J. 77, 1791\u20131798 (2013).","journal-title":"Circ. J."},{"key":"86090_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1507\/endocrj.K10E-289","volume":"58","author":"Y Kawagoe","year":"2011","unstructured":"Kawagoe, Y. et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr. J. 58, 171\u2013175 (2011).","journal-title":"Endocr. J."},{"key":"86090_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijcard.2011.01.062","volume":"158","author":"AE Pesaro","year":"2012","unstructured":"Pesaro, A. E. et al. Pleiotropic effects of ezetimibe\/simvastatin vs. high dose simvastatin. Int. J. Cardiol. 158, 400\u2013404 (2012).","journal-title":"Int. J. Cardiol."},{"key":"86090_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.atherosclerosis.2012.11.028","volume":"227","author":"J Westerink","year":"2013","unstructured":"Westerink, J. et al. High-dose statin monotherapy versus low-dose statin\/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis 227, 118\u2013124 (2013).","journal-title":"Atherosclerosis"},{"key":"86090_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","volume":"114","author":"CY Hsieh","year":"2015","unstructured":"Hsieh, C. Y., Chen, C. H., Li, C. Y. & Lai, M. L. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J. Formos Med. Assoc. 114, 254\u2013259 (2015).","journal-title":"J. Formos Med. Assoc."},{"key":"86090_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2013.11.036","volume":"232","author":"CH Chang","year":"2014","unstructured":"Chang, C. H. et al. Continuation of statin therapy and a decreased risk of atrial fibrillation\/flutter in patients with and without chronic kidney disease. Atherosclerosis 232, 224\u2013230 (2014).","journal-title":"Atherosclerosis"},{"key":"86090_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2188\/jea.JE20140076","volume":"24","author":"CL Cheng","year":"2014","unstructured":"Cheng, C. L. et al. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J. Epidemiol. 24, 500\u2013507 (2014).","journal-title":"J. Epidemiol."},{"key":"86090_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"CL Cheng","year":"2011","unstructured":"Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H. & Lai, M. L. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol. Drug Saf. 20, 236\u2013242 (2011).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"86090_CR35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","volume":"175","author":"AW Hsing","year":"2015","unstructured":"Hsing, A. W. & Ioannidis, J. P. Nationwide population science: lessons from the Taiwan national health insurance research database. JAMA Intern. Med. 175, 1527\u20131529 (2015).","journal-title":"JAMA Intern. Med."},{"key":"86090_CR36","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1210\/jc.2016-1831","volume":"101","author":"CH Liu","year":"2016","unstructured":"Liu, C. H. et al. Ezetimibe-simvastatin therapy reduce recurrent ischemic stroke risks in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 101, 2994\u20133001 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"86090_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13098-017-0272-7","volume":"9","author":"YR Li","year":"2017","unstructured":"Li, Y. R. et al. Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetol. Metab. Syndr. 9, 71 (2017).","journal-title":"Diabetol. Metab. Syndr."},{"key":"86090_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.09.018","volume":"267","author":"CM Chung","year":"2017","unstructured":"Chung, C. M. et al. Moderate to high intensity statin in dialysis patients after acute myocardial infarction: A national cohort study in Asia. Atherosclerosis 267, 158\u2013166 (2017).","journal-title":"Atherosclerosis"},{"key":"86090_CR39","first-page":"157","volume":"104","author":"CC Lin","year":"2005","unstructured":"Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C. & Tseng, F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J. Formos Med. Assoc. 104, 157\u2013163 (2005).","journal-title":"J. Formos Med. Assoc."},{"key":"86090_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2015.07.075","volume":"201","author":"CL Cheng","year":"2015","unstructured":"Cheng, C. L., Chien, H. C., Lee, C. H., Lin, S. J. & Yang, Y. H. Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan. Int. J. Cardiol. 201, 96\u2013101 (2015).","journal-title":"Int. J. Cardiol."},{"key":"86090_CR41","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/sim.8008","volume":"38","author":"PC Austin","year":"2019","unstructured":"Austin, P. C. & Fine, J. P. Propensity-score matching with competing risks in survival analysis. Stat. Med. 38, 751\u2013777 (2019).","journal-title":"Stat. Med."},{"key":"86090_CR42","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1161\/STROKEAHA.115.008097","volume":"46","author":"S Mendis","year":"2015","unstructured":"Mendis, S., Davis, S. & Norrving, B. Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 46, e121\u2013e122 (2015).","journal-title":"Stroke"},{"key":"86090_CR43","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M. & Brook, R. D. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J. Am. Coll. Cardiol. 65, 1552\u20131561 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86090_CR44","doi-asserted-by":"publisher","first-page":"26P","DOI":"10.1016\/j.amjcard.2006.09.017","volume":"98","author":"P Libby","year":"2006","unstructured":"Libby, P. & Sasiela, W. Plaque stabilization: can we turn theory into evidence?. Am. J. Cardiol. 98, 26P-33P (2006).","journal-title":"Am. J. Cardiol."},{"key":"86090_CR45","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","volume":"15","author":"JW Nawrocki","year":"1995","unstructured":"Nawrocki, J. W. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15, 678\u2013682 (1995).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"86090_CR46","first-page":"CD008226","volume":"2016","author":"SP Adams","year":"2015","unstructured":"Adams, S. P., Tsang, M. & Wright, J. M. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2016, CD008226 (2015).","journal-title":"Cochrane Database Syst Rev."},{"key":"86090_CR47","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532\u20132561 (2016).","journal-title":"Lancet"},{"key":"86090_CR48","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"HE Bays","year":"2004","unstructured":"Bays, H. E. et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe\/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26, 1758\u20131773 (2004).","journal-title":"Clin. Ther."},{"key":"86090_CR49","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1185\/030079906X132721","volume":"22","author":"AL Catapano","year":"2006","unstructured":"Catapano, A. L. et al. Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22, 2041\u20132053 (2006).","journal-title":"Curr. Med. Res. Opin."},{"issue":"372","key":"86090_CR50","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMe1507041","volume":"18","author":"JA Jarcho","year":"2015","unstructured":"Jarcho, J. A. & Keaney, J. F. Jr. Proof That Lower Is Better\u2013LDL Cholesterol and IMPROVE-IT. N. Engl. J .Med. 18(372), 2448\u20132450 (2015).","journal-title":"N. Engl. J .Med."},{"key":"86090_CR51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(04)16855-4","volume":"364","author":"RA Pauwels","year":"2004","unstructured":"Pauwels, R. A. & Rabe, K. F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364, 613\u2013620 (2004).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86090-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86090-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:38:20Z","timestamp":1670045900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86090-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86090"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86090-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6697"}}